India's Orchid sets up subsidiary in Japan
With the aim of penetrating the Japanese generics drug market, currently estimated to be worth around $2.5 billion and growing, India's Orchid Chemicals and Pharmaceuticals has established a subsidiary in that country under the name of Orchid Pharma Japan KK, in Tokyo.
No financial details relating to this investment were revealed, other than that the new unit is expected to generate turnover of some $100.0 million over the next five years through sales of its generic antibiotic, cephalosporin, and lifestyle disease products, reports the New Kerala. The newspaper adds that it is not clear whether Orchid plans to leverage its Chinese joint venture to supply the Japanese market.
Orchid has already made a successful foray into the US cephalosporin market and aims to do likewise in Europe, where it has filed 15 marketing authorization dossiers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze